Financial News · Live Terminal

Page 488 of 532

Leerink Partners Adjusts Price Target on Quest Diagnostics to $240 From $235, Maintains Outperform Rating

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $205.41, Change: $+9.10, Percent Change: +4.64%

$DGX

Wire110d ago

SolarEdge Technologies Launches Higher-Capacity Commercial Storage System in Europe, Asia

SolarEdge Technologies (SEDG) said Tuesday it launched its new higher-capacity commercial storage system CSS-OD 197 in Europe and Asia.The new system consists of a 197 kilowatt-hour-rated battery cabinet paired with one or two 50-kilowatt battery inverters and is scalable up to 1 megawatt and 4 megawatt-hours per site, the company said.The system supports a wide range of commercial and industrial storage use cases for medium- to large-scale commercial sites, SolarEdge said.SEDG shares were up past 5% Tuesday afternoon.Price: $41.85, Change: $+2.03, Percent Change: +5.10%

$SEDG

Wire110d ago

Life Time Likely to Post Softer Net Adds in Q1, RBC Capital Markets Says

Life Time (LTH) is likely to post softer net membership additions in fiscal Q1 due to the company's low-price 3p membership churn, RBC Capital Markets said in a Monday research note. The company is due to report results on May 5.For Q1, RBC said it expects net adds of 13,000 compared with Street's estimates of 21,000, but the quarter-to-date net adds are unlikely to be impacted by the Middle East conflict. It reiterated its revenue and EBITDA forecasts for 2026 and 2027.The 3p membership churn is at a lower rate than 1p membership, and the overall impact on the model is expected to be negligible, analysts wrote.RBC reiterated its outperform rating on the stock and price target of $38.Price: $27.82, Change: $-0.76, Percent Change: -2.66%

$LTH

Wire110d ago

Autodesk Likely to Benefit From AI Tailwinds, Durable Growth Outlook, Oppenheimer Says

Autodesk (ADSK) is poised to benefit from AI-driven tailwinds and deliver durable high-teens to low 20% earnings growth, supported by high-single-digit to low-double-digit revenue growth and consistent mid- to long-term margin expansion, Oppenheimer said Tuesday in a note.While Autodesk is not immune to macro conditions, including the Middle East conflict, where the region accounts for a mid-single-digit percentage of revenue, its diversified geographic and customer base provides resilience.The firm added that if macro risks intensify, it sees potential for management to de-risk the full-year outlook, similar to its 2026 guidance following tariffs. Partner checks indicate no meaningful impact on renewal or sales activity from the conflict.Oppenheimer said Autodesk benefits from proprietary data, end-market context, intellectual property protections, and data permissions, which make its position difficult for AI startups to replicate, while also highlighting AI as a broader tailwind across the AEC technology stack.The firm also pointed to changes in sales incentives and a greater focus on net new business, particularly Construction Cloud, as part of an evolving go-to-market strategy.It further highlighted expansion into operations as a significant long-term opportunity, with a larger addressable market that extends Autodesk's monetization window and could be supported by future acquisitions, according to the note.Oppenheimer has an outperform rating with a $325 price target.Price: $248.28, Change: $+2.97, Percent Change: +1.21%

$ADSK

Wire110d ago

Evercore ISI Adjusts Danaher Price Target to $232 From $225, Maintains Outperform Rating

Danaher (DHR) has an average rating of Buy and mean price target of $254.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $192.63, Change: $-2.87, Percent Change: -1.47%

$DHR

Wire110d ago

TE Connectivity's Stock 'Recovery' Signals Strong Market Position, Oppenheimer Says

TE Connectivity (TEL) is expected to report earnings Wednesday following a stock recovery that reflects the company's strong market position despite recent stock price volatility, Oppenheimer said in a report Tuesday.The company's shares recently rebounded from eight-month lows, the report said. The previous selloff was "narrowly focused" on fears that new data center "architectures" would disrupt its artificial intelligence portfolio, but the firm is poised for "net market expansion" driven by the massive scale of AI infrastructure, according to the report.The company has issued fiscal year 2026 AI revenue guidance of $2.2 billion, the report said. Oppenheimer said TE Connectivity is "particularly well-positioned" in power connectivity for "higher-voltage data centers" and is seeing broad-based growth across every major "hyperscaler" customer.Oppenheimer has an outperform rating on TE Connectivity with a $285 price target.Price: $248.51, Change: $+0.85, Percent Change: +0.34%

$TEL

Wire110d ago

Eightco Reports $336 Million in Holdings Including OpenAI

Eightco (ORBS) said Tuesday that it had total holdings of about $336 million as of Monday, including a $90 million stake in OpenAI.The company said it also had equity valued at $25 million in Beast Industries. 283,452,700 Worldcoin tokens valued at $0.27 apiece, 11,068 Ethereum coins, and $118 million in total cash and stablecoins.Eightco shares were more than 3% lower in Tuesday trading.Price: $0.97, Change: $-0.04, Percent Change: -3.56%

$ORBS

Wire110d ago

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

Axsome Therapeutics' (AXSM) shares are likely facing an "attractive setup" ahead of the US Food and Drug Administration's approval decision of a label expansion of Auvelity into Alzheimer's disease agitation, Oppenheimer said in a note Tuesday.Oppenheimer said it forecasts a 20% upside with a 95% probability versus a 35% downside upon the FDA's decision, reflecting the investment firm's about $2 billion sales estimate, with a priority review for the drug backing its conviction.The investment firm noted Auvelity was originally approved for major depressive disorder in Q3 2022, and was also given breakthrough therapy designation for a potential label expansion into Alzheimer's disease agitation.Oppenheimer said it sees "distinct commercial advantages" for Auvelity, as it may "compete on clean safety, which also justifies formulary positioning and longer-term use" compared with competing Alzheimer's disease agitation drug Rexulti.Meanwhile, Auvelity is also competitively well-positioned compared with candidate drugs in development like Cobenfy, which are "far behind," the note said.Oppenheimer has an outperform rating on Axsome and a $220 price target.Price: $183.26, Change: $-5.43, Percent Change: -2.88%

$AXSM

Wire110d ago

Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

Whitehawk Therapeutics (WHWK) presented "solid" preclinical datasets for its early stage antibody drug conjugates, or ADCs, indicating "substantial clinical evidence" of their potential efficacy against solid tumor targets, Oppenheimer said in a Monday note.Out of the company's portfolio of ADCs, HWK-007 and HWK-016 are currently under clinical studies and HWK-206 is expected to follow in Q3, the note said.HWK-007, which targets Protein Tyrosine Kinase 7 or PTK7, demonstrated "potent activity," while HWK-016 showed "clear superiority" to an earlier ADC targeting Mucin 16 or MUC16, Oppenheimer said. HWK-206 also showed enhanced properties against Seizure-Related Homolog Protein 6 or SEZ6, the firm added.Oppenheimer has an outperform rating and $5 price target on Whitehawk Therapeutics.Price: $4.21, Change: $-0.02, Percent Change: -0.47%

$WHWK

Wire110d ago

Palo Alto Networks Seen Undervalued as Portfolio Strengthens, Berenberg Says

Palo Alto Networks' (PANW) valuation multiples trail the company's improving portfolio quality and growing scale, Berenberg said Tuesday in a report.The company "is a rare quality compounder in cybersecurity, with best-in-class execution, multiple growth engines, and strong product breadth," the report said.Consensus models assume the company will convert about 59 customers per quarter to broader product bundles, rising to about 2,600 by fiscal 2030, Berenberg said. Even 2,500 to 3,500 such conversions by 2030 may not represent an upper limit, with momentum expected to build following the CyberArk and Chronosphere acquisitions, the report said.Berenberg initiated coverage on Palo Alto Networks stock with a buy rating and a $215 price target.Price: $175.63, Change: $+6.07, Percent Change: +3.58%

$PANW

Wire110d ago

Intel Likely to Post a Fiscal Q1 Beat, RBC Capital Markets Says

Intel (INTC) is likely to post a slight fiscal Q1 beat on robust server CPU demand while the PC market holds up for now, RBC Capital Markets said in a Monday research report. The company is due to report results on April 23.RBC said it expects fiscal Q1 adjusted EPS of $0 on revenue of $12.2 billion with up to 200 basis points of upside to gross margin forecast due to healthy pricing. For Q2, RBC expects adjusted EPS of $0.09 on revenue of $13.1 billion.Wafer supply roadblocks could limit near-term upside while PC market faces headwinds in H2 from memory chip tightness, analysts wrote.The stock valuation reflects optimism around the company's Foundry unit, while server demand will keep benefiting from agentic AI, according to RBC.RBC reiterated its sector perform rating on the stock and price target of $48 per share.Price: $66.56, Change: $+0.86, Percent Change: +1.31%

$INTC

Wire110d ago

Ingram Micro Likely to Post Q1 Beat on PC Strength, Xvantage Tailwinds, RBC Says

Ingram Micro (INGM) is likely to post a fiscal Q1 beat due to PC strength from pull-forward demand, with longer-term margin expansion expected from its Xvantage platform and AI-related opportunities, RBC Capital Markets said.The brokerage said in a Monday research report that it estimates fiscal Q1 revenue growth of 4.6% to $12.84 billion, gross profit of $873 million and adjusted EPS of $0.76, above the consensus of $0.72.It sees demand supported by large enterprise clients and outsized growth in the Asia-Pacific region and highlights long-term opportunity in GPU and AI infrastructure deals.The company is positioned to drive margin expansion driven by Xvantage Phase 3, which utilizes data to drive organic growth without incremental operating expenditures, expected to improve revenue quality.RBC models fiscal 2026 revenue of $54.04 billion and adjusted EPS of $3.32, compared with consensus of $53.71 billion and $3.24, respectively.The firm reiterated its outperform rating on the stock and raised its price target to $33 per share from $24.Shares of Ingram were up more than 3% in Tuesday trading.Price: $31.27, Change: $+0.96, Percent Change: +3.17%

$INGM

Wire110d ago

Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says

Passage Bio (PASG) is "undervalued" given PBFT02's distinct profile, with the US Food and Drug Administration's feedback extending the path to approval, Oppenheimer said in a note Tuesday.The analysts said the company on Monday released data from its upliFT-D study along with feedback from the FDA. The update was mixed. On the positive side, the clinical data suggests PFBT02 may still be worth pursuing, especially in patients with milder disease. However, the FDA's feedback was a setback. It indicated that a single-arm pivotal study would not be sufficient for approval.The analysts said they see the promise of the progranulin target in certain neurodegenerative diseases. Although other programs in this area have struggled to show clear benefits in frontotemporal dementia, or FTD, PBFT02 stands out due to its mechanism, administration, and the data seen so far. As a one-time, non-surgical treatment, it could offer a strong commercial advantage if approved."We view Passage Bio as undervalued given PBFT02's relative profile versus others in the pipeline for FTD, which remains highly underserved," the analysts added.Oppenheimer adjusted its price target on Passage Bio from $30 to $15 while maintaining its outperform rating.Price: $5.96, Change: $-0.30, Percent Change: -4.72%

$PASG

Wire110d ago

Onto Innovation's Rigaku Deal Boosts Position in Semiconductor Process Control, Oppenheimer Says

Onto Innovation's (ONTO) acquisition of a 27% stake in X-ray hardware firm Rigaku strengthens its competitive edge in next-generation semiconductor process control, Oppenheimer said in a note Monday.The company is anticipating that X-ray metrology will become much more important, and combining its software with Rigaku's hardware will enable it to capture a core position in the metrology category before it fully matures, analysts said.Onto's investment in Rigaku, valued at about $710 million, is expected to be financially accretive by late 2026, and give Onto a board seat on Rigaku for strategic alignment, according to the note.Advanced V-NAND and DRAM customers have already adopted the integrated systems, while there is growing interest from other logic and memory manufacturers, analysts said.Oppenheimer reiterated its outperform rating on the stock, with a $350 price target.Price: $291.76, Change: $-3.33, Percent Change: -1.13%

$ONTO

Wire110d ago

Dutch Bros' Q1 Beat May Lift Full-Year 2026 Guidance, Competition Remains an Overhang, RBC Says

Dutch Bros' (BROS) Q1 beat could allow higher full-year 2026 guidance, but competition remains the primary overhang on the stock, which will be difficult to disprove in the Q1 print, RBC Capital Markets said Monday in a note.Despite rising competition, RBC said it is constructive on the stock and does not expect Starbucks' (SBUX) or McDonalds' (MCD) beverage launches to have a notable impact on Dutch Bros' traffic growth.Same-store-sales growth will be a key focus in Q1, where RBC expects underlying traffic momentum, mobile ordering, and food to drive upside versus Street's 5.7% estimate.Unit growth is a core pillar of RBC's long-term thesis for Dutch Bros as it targets 2,029 units by 2029. The brokerage said Q1 could come in above Street consensus of 33 net adds, while RBC estimates about 40 net adds.RBC said it expects Dutch Bros to remain a fundamental outperformer within its coverage as both category and idiosyncratic drivers should allow for upside versus consensus in Q1.RBC maintained an outperform rating on Dutch Bros with a price target of $75.Price: $54.54, Change: $-0.08, Percent Change: -0.15%

$BROS

Wire110d ago

Lockheed Martin Advances Naval Missile Defense With PAC-3 MSE Integration Contract

Lockheed Martin (LMT) said Tuesday it has been awarded a US Navy contract to develop and integrate its PAC-3 Missile Segment Enhancement into the Aegis Combat System, marking its first integration of the system into a naval platform.The program is designed to enhance the Navy's integrated air and missile defense capabilities, enabling warships to engage a broader range of threats, including ballistic, cruise, and emerging hypersonic missiles, the company said.Shares of Lockheed Martin were down 2.1% in Tuesday trading.Price: $569.20, Change: $-12.08, Percent Change: -2.08%

$LMT

Wire110d ago

Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says

Climb Bio (CLYM) is drawing increased analyst optimism following updated expectations for its immunology pipeline, particularly its investigational therapies for IgA nephropathy, Oppenheimer said in a Tuesday note.Oppenheimer highlighted growing confidence in Climb Bio's anti-APRIL programs, including CLYM116, citing potential best-in-class efficacy, stronger-than-expected proteinuria reduction, longer dosing intervals, and a favorable safety profile as key differentiators.According to the report, upcoming clinical readouts for subcutaneous budoprutug and CLYM116 could serve as key catalysts, potentially validating Climb Bio's IgAN approach, with strong pricing dynamics supporting commercial upside if results are positive.Oppenheimer maintained its outperform rating on the stock and raised its price target to $18 from $10.Shares of Climb Bio were up more than 6% in Tuesday trading.Price: $9.49, Change: $+0.52, Percent Change: +5.80%

$CLYM

Wire110d ago

Navan's Fiscal 2027 Guidance is 'Highly Achievable,' Oppenheimer Says

Navan's (NAVN) fiscal 2027 guidance is "highly achievable" due to robust demand for business travel while its fast-growing AI platform accelerates enterprise wins, expands gross margins, and boosts traveler personalization, Oppenheimer said in a Tuesday research report.Airline corporate travel demand appears steady despite the Middle East conflict and elevated jet fuel prices, analysts wrote.The brokerage said the stock is now its top small- and mid-cap pick. It expects growing enterprise adoption driving upward estimate revisions, which is currently not priced into the stock, trading at a 60% discount to peers.The company's virtual agent oversees the majority of client engagement and has been a key driver of gross margin expansion in recent years, according to the note.The brokerage reiterated its outperform rating on the stock and boosted its price target to $20 from $17.Price: $15.94, Change: $+0.59, Percent Change: +3.84%

$NAVN

Wire110d ago

Cheesecake Factory has 'Intriguing' Setup Against Consensus in 2026, Oppenheimer Says

Cheesecake Factory (CAKE) has an "intriguing" setup against consensus in 2026 where same-store sales and EPS forecasts now tilt conservatively, Oppenheimer said Tuesday.According to the note, the company's core customer remains unaffected amid macro pressures impacting the broader industry. This dynamic, along with Oppenheimer's analysis of consensus, identifies a strong setup against Street's Q1 and Q2 same-store sales forecasts of 0.6% and 0.7%, respectively.The brokerage believes risk/reward skews favorably against Street's full-year 2026 same-store-sales forecast of 1.1%. Quarterly SSS forecasts possibly discount healthier underlying momentum, new company-specific drivers, and easier comparisons, the brokerage added.Management's Q1 guidance implied SSS mid-point of 1% and EPS near $1. Meanwhile, Oppenheimer forecasts 1.0% SSS and EPS of $1.01, versus Street consensus of 0.6% and $1, respectively.The brokerage slightly lifted its 2026 and 2027 EPS estimates to to $4.04 and $4.48 from $4.03 and 4.46, respectively.The company is scheduled to report Q1 results on April 29.Oppenheimer maintained an outperform rating on Cheesecake Factory and raised the price target to $72 from $68.Price: $61.90, Change: $-0.24, Percent Change: -0.39%

$CAKE

Showing 9741-9760 of 10633

Wire110d ago

Financial News · Live Terminal

Leerink Partners Adjusts Price Target on Quest Diagnostics to $240 From $235, Maintains Outperform Rating

SolarEdge Technologies Launches Higher-Capacity Commercial Storage System in Europe, Asia

Life Time Likely to Post Softer Net Adds in Q1, RBC Capital Markets Says

Autodesk Likely to Benefit From AI Tailwinds, Durable Growth Outlook, Oppenheimer Says

Evercore ISI Adjusts Danaher Price Target to $232 From $225, Maintains Outperform Rating

TE Connectivity's Stock 'Recovery' Signals Strong Market Position, Oppenheimer Says

Eightco Reports $336 Million in Holdings Including OpenAI

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

Palo Alto Networks Seen Undervalued as Portfolio Strengthens, Berenberg Says

Intel Likely to Post a Fiscal Q1 Beat, RBC Capital Markets Says

Ingram Micro Likely to Post Q1 Beat on PC Strength, Xvantage Tailwinds, RBC Says

Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says

Top Midday Stories: UnitedHealth Raises 2026 EPS Guidance, Shares Soar; Cook to Step Down as Apple CEO

Onto Innovation's Rigaku Deal Boosts Position in Semiconductor Process Control, Oppenheimer Says

Dutch Bros' Q1 Beat May Lift Full-Year 2026 Guidance, Competition Remains an Overhang, RBC Says

Lockheed Martin Advances Naval Missile Defense With PAC-3 MSE Integration Contract

Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says

Navan's Fiscal 2027 Guidance is 'Highly Achievable,' Oppenheimer Says

Cheesecake Factory has 'Intriguing' Setup Against Consensus in 2026, Oppenheimer Says

Leerink Partners Adjusts Price Target on Quest Diagnostics to $240 From $235, Maintains Outperform Rating

SolarEdge Technologies Launches Higher-Capacity Commercial Storage System in Europe, Asia

Life Time Likely to Post Softer Net Adds in Q1, RBC Capital Markets Says

Autodesk Likely to Benefit From AI Tailwinds, Durable Growth Outlook, Oppenheimer Says

Evercore ISI Adjusts Danaher Price Target to $232 From $225, Maintains Outperform Rating

TE Connectivity's Stock 'Recovery' Signals Strong Market Position, Oppenheimer Says

Eightco Reports $336 Million in Holdings Including OpenAI

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

Palo Alto Networks Seen Undervalued as Portfolio Strengthens, Berenberg Says

Intel Likely to Post a Fiscal Q1 Beat, RBC Capital Markets Says

Ingram Micro Likely to Post Q1 Beat on PC Strength, Xvantage Tailwinds, RBC Says

Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says

Top Midday Stories: UnitedHealth Raises 2026 EPS Guidance, Shares Soar; Cook to Step Down as Apple CEO

Onto Innovation's Rigaku Deal Boosts Position in Semiconductor Process Control, Oppenheimer Says

Dutch Bros' Q1 Beat May Lift Full-Year 2026 Guidance, Competition Remains an Overhang, RBC Says

Lockheed Martin Advances Naval Missile Defense With PAC-3 MSE Integration Contract

Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says

Navan's Fiscal 2027 Guidance is 'Highly Achievable,' Oppenheimer Says

Cheesecake Factory has 'Intriguing' Setup Against Consensus in 2026, Oppenheimer Says